BIO-GATE AG (BIG1.DE) Fundamental Analysis & Valuation

FRA:BIG1 • DE000BGAG981

Current stock price

0.66 EUR
+0.03 (+3.94%)
Last:

This BIG1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BIG1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BIG1 has reported negative net income.
  • BIG1 had a negative operating cash flow in the past year.
  • BIG1 had negative earnings in each of the past 5 years.
  • In the past 5 years BIG1 always reported negative operating cash flow.
BIG1.DE Yearly Net Income VS EBIT VS OCF VS FCFBIG1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500K -1M -1.5M -2M -2.5M

1.2 Ratios

  • The Return On Assets of BIG1 (-32.97%) is worse than 91.67% of its industry peers.
  • BIG1 has a worse Return On Equity (-151.10%) than 90.28% of its industry peers.
Industry RankSector Rank
ROA -32.97%
ROE -151.1%
ROIC N/A
ROA(3y)-33.66%
ROA(5y)-27.14%
ROE(3y)-61.46%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
BIG1.DE Yearly ROA, ROE, ROICBIG1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • BIG1 has a better Gross Margin (57.72%) than 86.11% of its industry peers.
  • In the last couple of years the Gross Margin of BIG1 has declined.
  • BIG1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.52%
GM growth 5Y-2.6%
BIG1.DE Yearly Profit, Operating, Gross MarginsBIG1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BIG1.DE Health Analysis

2.1 Basic Checks

  • BIG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BIG1 has about the same amout of shares outstanding than it did 1 year ago.
  • BIG1 has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for BIG1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BIG1.DE Yearly Shares OutstandingBIG1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
BIG1.DE Yearly Total Debt VS Total AssetsBIG1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • Based on the Altman-Z score of -2.81, we must say that BIG1 is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BIG1 (-2.81) is worse than 88.89% of its industry peers.
  • BIG1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.81
ROIC/WACCN/A
WACC7.55%
BIG1.DE Yearly LT Debt VS Equity VS FCFBIG1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • A Current Ratio of 1.85 indicates that BIG1 should not have too much problems paying its short term obligations.
  • BIG1's Current ratio of 1.85 is in line compared to the rest of the industry. BIG1 outperforms 45.83% of its industry peers.
  • BIG1 has a Quick Ratio of 1.85. This is a bad value and indicates that BIG1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BIG1's Quick ratio of 0.55 is on the low side compared to the rest of the industry. BIG1 is outperformed by 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 0.55
BIG1.DE Yearly Current Assets VS Current LiabilitesBIG1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIG1.DE Growth Analysis

3.1 Past

  • BIG1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.80%, which is quite impressive.
  • Looking at the last year, BIG1 shows a decrease in Revenue. The Revenue has decreased by -7.53% in the last year.
  • BIG1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.13% yearly.
EPS 1Y (TTM)31.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.52%
Revenue 1Y (TTM)-7.53%
Revenue growth 3Y4.19%
Revenue growth 5Y15.13%
Sales Q2Q%-2.1%

3.2 Future

  • Based on estimates for the next years, BIG1 will show a very strong growth in Earnings Per Share. The EPS will grow by 25.35% on average per year.
  • BIG1 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.30% yearly.
EPS Next Y27.27%
EPS Next 2Y30.27%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue Next Year0.33%
Revenue Next 2Y4.18%
Revenue Next 3Y7.3%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BIG1.DE Yearly Revenue VS EstimatesBIG1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
BIG1.DE Yearly EPS VS EstimatesBIG1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

1

4. BIG1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BIG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIG1. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIG1.DE Price Earnings VS Forward Price EarningsBIG1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIG1.DE Per share dataBIG1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

  • BIG1's earnings are expected to grow with 25.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.27%
EPS Next 3Y25.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIG1.DE Dividend Analysis

5.1 Amount

  • BIG1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIG1.DE Fundamentals: All Metrics, Ratios and Statistics

BIO-GATE AG

FRA:BIG1 (4/29/2026, 7:00:00 PM)

0.66

+0.03 (+3.94%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Industry Strength54.73
Industry Growth36.67
Earnings (Last)03-02
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.8%
Ins Owner ChangeN/A
Market Cap6.10M
Revenue(TTM)6.98M
Net Income(TTM)-1.38M
Analysts82.5
Price Target3.06 (363.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.35%
EPS NY rev (3m)-4.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.87
P/FCF N/A
P/OCF N/A
P/B 6.68
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.76
BVpS0.1
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -32.97%
ROE -151.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.72%
FCFM N/A
ROA(3y)-33.66%
ROA(5y)-27.14%
ROE(3y)-61.46%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.52%
GM growth 5Y-2.6%
F-Score4
Asset Turnover1.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.72%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 0.55
Altman-Z -2.81
F-Score4
WACC7.55%
ROIC/WACCN/A
Cap/Depr(3y)91.79%
Cap/Depr(5y)118.01%
Cap/Sales(3y)3.64%
Cap/Sales(5y)4.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.52%
EPS Next Y27.27%
EPS Next 2Y30.27%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-7.53%
Revenue growth 3Y4.19%
Revenue growth 5Y15.13%
Sales Q2Q%-2.1%
Revenue Next Year0.33%
Revenue Next 2Y4.18%
Revenue Next 3Y7.3%
Revenue Next 5YN/A
EBIT growth 1Y30.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.36%
EBIT Next 3Y30.3%
EBIT Next 5YN/A
FCF growth 1Y65.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.93%
OCF growth 3YN/A
OCF growth 5YN/A

BIO-GATE AG / BIG1.DE Fundamental Analysis FAQ

What is the fundamental rating for BIG1 stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIG1.DE.


What is the valuation status for BIG1 stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO-GATE AG (BIG1.DE). This can be considered as Overvalued.


Can you provide the profitability details for BIO-GATE AG?

BIO-GATE AG (BIG1.DE) has a profitability rating of 1 / 10.


What is the financial health of BIO-GATE AG (BIG1.DE) stock?

The financial health rating of BIO-GATE AG (BIG1.DE) is 5 / 10.